Methods for treating chronic obstructive pulmonary disease

US11484531B2 · kind B2 · utility

Assignee

• Theravance Biopharma R&D IP, LLC · US

Inventors

• Christopher Barnes · Bad Soden, DE
• Glenn D. Crater · Raleigh, US
• Edmund J. Moran · San Francisco, US
• Srikanth Pendyala · South San Francisco, US

Key dates

• Filing date: Aug 29, 2019
• Grant date: Nov 1, 2022
• Expiry date: Oct 23, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods for treating chronic obstructive pulmonary disease (COPD) in a patient are disclosed. In the methods, a patient having COPD is selected for treatment based on the patient's peak inspiratory flow rate (PIFR) and percent predicted force expiratory volume in one second (FEV1); and a bronchodilator is administered to the selected patient using a nebulizer. Administration of a bronchodilator to patients having low PIFR and a percent predicted FEV1 less than 50 percent using a nebulizer as the inhalation delivery device provides significantly greater improvements in trough FEV1 and trough forced vital capacity (FVC) compared to administration of a bronchodilator to such patients using a dry powder inhaler.